We are live on ! Find out more
ITDD icon

iShares LifePath Target Date 2040 ETF

2 hedge funds and large institutions have $812K invested in iShares LifePath Target Date 2040 ETF in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

5.51% less ownership

Funds ownership: 9.53% → 4.01% (-5.5%)

55% less capital invested

Capital invested by funds: $1.82M → $812K (-$1.01M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$835K
2
Citadel Advisors
Citadel Advisors
Florida
-$239K

ITDD Hedge Fund Activity: Q1 2024 in Review

2 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in iShares LifePath Target Date 2040 ETF (ITDD) for Q1 2024, worth a combined $812K — down 55% from $1.82M a quarter earlier.

Fund positioning in ITDD was balanced in Q1 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was BlackRock, cutting an estimated $835K.

  • 2 institutional investors held iShares LifePath Target Date 2040 ETF (ITDD) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $812K of iShares LifePath Target Date 2040 ETF stock for Q1 2024, down 55% quarter-over-quarter.
  • 0 funds opened new iShares LifePath Target Date 2040 ETF positions in Q1 2024 and 0 closed out.
  • The largest iShares LifePath Target Date 2040 ETF seller in Q1 2024 was BlackRock, an estimated $835K sold.

Based on aggregated 13F filings for Q1 2024.